Genomic landscape of follicular lymphoma across a wide spectrum of clinical behaviors.

While some follicular lymphoma (FL) patients do not require treatment or experience prolonged responses, others relapse early, and little is known about genetic alterations specific to patients with a particular clinical behavior. We selected 56 grade 1-3A FL patients according to their need of trea...

Descripción completa

Detalles Bibliográficos
Autores: Mozas, Pablo, López González, Cristina, Grau Cuesta, Marta, Nadeu Prat, Ferran, Clot Razquin, Guillem, Valle, Sara, Kulis, Marta, Navarro López, Alba, Ramis Zaldivar, Joan Enric, González Farré. Blanca, Rivas Delgado, Alfredo, Rivero, Andrea, Frigola, Gerard, Balagué Ponz, Olga, Giné Soca, Eva, Delgado, Julio, Villamor i Casas, Neus, Matutes, Estella, Magnano, Laura, García Sanz, Ramón, Huet, Sarah, Russell. Robert B., Campo Güerri, Elias, López Guillermo, Armando, Beà Bobet, Sílvia M.
Tipo de recurso: artículo
Estado:Versión aceptada para publicación
Fecha de publicación:2023
País:España
Institución:Varias* (Consorci de Biblioteques Universitáries de Catalunya, Centre de Serveis Científics i Acadèmics de Catalunya)
Repositorio:Recercat. Dipósit de la Recerca de Catalunya
OAI Identifier:oai:recercat.cat:2445/219869
Acceso en línea:https://hdl.handle.net/2445/219869
Access Level:acceso abierto
Palabra clave:Limfomes
Genòmica
Pronòstic mèdic
Lymphomas
Genomics
Prognosis
Descripción
Sumario:While some follicular lymphoma (FL) patients do not require treatment or experience prolonged responses, others relapse early, and little is known about genetic alterations specific to patients with a particular clinical behavior. We selected 56 grade 1-3A FL patients according to their need of treatment or timing of relapse: never treated (n = 7), non-relapsed (19), late relapse (14), early relapse or POD24 (11), and primary refractory (5). We analyzed 56 diagnostic and 12 paired relapse lymphoid tissue biopsies and performed copy number alteration (CNA) analysis and next generation sequencing (NGS). We identified six focal driver losses (1p36.32, 6p21.32, 6q14.1, 6q23.3, 9p21.3, 10q23.33) and 1p36.33 copy-neutral loss of heterozygosity (CN-LOH). By integrating CNA and NGS results, the most frequently altered genes/regions were KMT2D (79%), CREBBP (67%), TNFRSF14 (46%) and BCL2 (40%). Although we found that mutations in PIM1, FOXO1 and TMEM30A were associated with an adverse clinical behavior, definitive conclusions cannot be drawn, due to the small sample size. We identified common precursor cells harboring early oncogenic alterations of the KMT2D, CREBBP, TNFRSF14 and EP300 genes and 16p13.3-p13.2 CN-LOH. Finally, we established the functional consequences of mutations by means of protein modeling (CD79B, PLCG2, PIM1, MCL1 and IRF8). These data expand the knowledge on the genomics behind the heterogeneous FL population and, upon replication in larger cohorts, could contribute to risk stratification and the development of targeted therapies.

Similares en LA Referencia